Powered by

Overview

Carina Biotech is an Australian immuno-oncology company developing CAR-T and other adoptive cell therapies for the treatment of solid cancers.

In addition to its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer, Carina has a deep pipeline of CAR-T programs as well as platform technologies for the positioning of CAR-T cells within solid tumours, to enhance potency and induce “serial” killing that is capable of memory.

The company has a pipeline of novel CAR-T programs in preclinical development for the treatment of a range of solid cancers, with the lead program targeting LGR5, a cancer stem cell marker.

In addition, the company has developed a proprietary multi-functional chemokine receptor platform to enable CAR-T cell arming, homing and access to tumours and an efficient CAR-T cell manufacturing platform to increase efficacy and persistence within tumours.

Using its proprietary chemokine receptor platform, Carina aims to improve access to and infiltration of solid cancers by CAR-containing cells, resulting in more potent and specific cancer killing and reduced off-target effects.

Carina also has a fully integrated, proprietary manufacturing process that has both a proprietary 5-day manufacturing process and improved CAR-T cell quality, capable of delivering robust “serial-killing” CAR-T cells to patients.

Delegates

Deborah-RATHJEN_50_230524_2-3-no-Bkgd.jpg
Deborah Rathjen
CEO & Managing Director
Carina_BG_001-orange-for-slides.png